Quiver Quantitative

FAQ Chagee's net revenues for the second quarter of 2026 were RMB3,414.6 million (US$503.3 million), a 2.5% increase year-over-year. Chagee had 47.1 million active members as of June 30, 2026, down from 50.0 million in the previous quarter. The total GMV generated by Chagee in the second quarter of 2026 was RMB7,660.3 million. Chagee's share repurchase program allows for the repurchase of up to US$150 million of its shares over twelve months.

FAQ iBio announced the initiation of the Phase 1 clinical trial for IBIO-600 and advanced its programs IBIO-610 and IBIO-800 into IND-enabling studies. iBio reported revenues of approximately $0.1 million, a decrease of $0.3 million compared to the previous year, with increased R&D expenses. iBio's long-acting antibodies target obesity, cardiometabolic conditions, and cardiopulmonary diseases to improve body composition and metabolic health.

Range Resources Corporation announced a quarterly cash dividend of $0.10 per share, payable on September 25, 2026. Quiver AI Summary Range Resources Corporation announced a quarterly cash dividend of $0.10 per common share for the third quarter, which will be payable on September 25, 2026, to stockholders on record as of September 11, 2026. The company, based in Fort Worth, Texas, is an independent natural gas and NGL producer with a focus on the Appalachian Basin.

FAQ MoneyHero will release its second quarter 2026 results on September 11, 2026, before market opens. The conference call will take place at 8:00 a.m. EDT on September 11, 2026. You can access the webcast through the registration link provided in the press release. The webcast replay will be available on MoneyHero's Investor Relations website for 12 months after the event.

BXCL501, a novel dexmedetomidine sublingual film, is under FDA review for potential at-home (outpatient) use for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. Agreement is part of a court-supervised sale process with BioXcel Therapeutics, Inc. and remains subject to bankruptcy court approval, potential higher bids, and customary closing conditions.

FAQ For Q2 2026, Jiayin reported a net loss of RMB183.6 million and a decrease in transaction volume by 74.4% year-over-year. Net revenue dropped by 60.9% to RMB736.9 million in Q2 2026 compared to the same quarter in 2025. The company faced a loss from operations of RMB246.7 million, contrasting with income from operations in the previous year. Yes, Jiayin suspended its dividend for the fiscal year 2026 to support capital investments and develop its strategy.

BioXcel Therapeutics intends to complete a court-supervised sale transaction, in an effort to maximize value for all stakeholders Teva Pharmaceuticals to serve as “stalking horse” bidder in a court-supervised 363 auction process BioXcel Therapeutics has secured a commitment for debtor-in-possession (DIP) financing to support ongoing operations NEW HAVEN, Conn., Aug. 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc.

Interim Analysis of the First Six Patients to Complete 12 Weeks of Treatment Met Pre-Specified Alpha Adjusted Target for Primary Endpoint with Statistical Significance Four of Six (66.7%) Participants Achieved the Target 1-Grade or Greater Improvement in Investigator Global Assessment at Week 12 (p=0.0087) With Statistical Significance versus the Pre-Specified Alpha of 0.0215 Key Secondary Endpoint of Global Impression of Change Also Achieved Statistical Significance at Week 12 (p=0.0070)...

FAQ Immuron reported record FY26 sales of A$7.7 million with a 6% growth compared to the previous year. The Australian market experienced double-digit growth at 10% despite inventory reductions by Chemist Warehouse/Sigma. Immuron focuses on developing oral therapies targeting infectious diseases, including products like Travelan® and IMM-529. Recent milestones include U.S. FDA approval for IMM-529 and significant growth in Travelan® sales in the U.S. and Australia.

FAQ Netcapital Inc. received a delinquency notification regarding its non-compliance with filing the Annual Report on Form 10-K. The company has 60 calendar days, until October 23, 2026, to submit a compliance plan to Nasdaq. No, the Notice does not have an immediate effect on the listing or trading of the Company’s common stock or warrants. If accepted, Nasdaq may grant an extension of up to 180 additional days to regain compliance. Netcapital Inc.